Comparing two versions of a new weight-loss medication
Treatments studied
Part of Hormones & metabolism clinical trials.
This study compares two different versions of an investigational weight-loss medication (cagrilintide) against a placebo to see which is more effective and safe for people with excess weight. Participation involves receiving injections and regular check-ins to monitor your progress.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your body mass index (BMI) is 30 or higher, or at least 27 with a weight-related condition like high blood pressure, high cholesterol, sleep apnea, or heart disease.
- You have never been diagnosed with type 1 or type 2 diabetes.
- You have not taken any amylin-based weight-loss medication in the past (like pramlintide).
- You have not taken any prescription weight-loss medication in the last 6 months, and you don't plan to start any during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests different formulations of cagrilintide, a new medication, to see how the body absorbs and processes each version. Cagrilintide may help with weight management. Researchers will measure blood levels after you receive multiple doses.
This study tests a new injectable medication called cagrilintide for people with obesity who had to stop GLP-1 drugs (like Ozempic or Wegovy) because of stomach problems. The goal is to see if cagrilintide causes fewer stomach side effects while still helping with weight.
This early-stage study tests a new medication called cagrilintide to see how it influences appetite and food intake in adults with overweight or obesity. Researchers want to understand if this drug could help people feel fuller and eat less.
This study tests whether a new combination medication called CagriSema (in two different doses) helps people with obesity lose weight. You may qualify if you're 18 or older, have a BMI of 35 or higher, and either don't have type 2 diabetes or have it well-controlled.
This trial tests two new medicines (cagrilintide and CagriSema) to see if they help children and teens lose weight. It's for young people who have tried lifestyle changes without enough success.
This study tests how two medicines, cagrilintide and semaglutide, affect your metabolism compared to diet alone. It may help you understand how weight loss changes your body's energy use.
Hear when a new Overweight trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.